FRANKLIN, Tenn. / Nov 09, 2023 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two conferences in November.
On Tuesday, November 14, 2023, the Company will participate in the Wolfe Research Healthcare Conference 2023, which is being held November 14 - 15, 2023, in New York, New York. The Company’s presentation will be at 1:15 p.m. Eastern Time / 12:15 p.m. Central Time.
On Thursday, November 16, 2023, the Company will participate in the Stephens Annual Investment Conference, which is being held November 14 - 16, 2023, in Nashville, Tennessee. The Company’s presentation will be at 2:00 p.m. Eastern Time / 1:00 p.m. Central Time.
The live webcast of both presentations webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,100 beds in 39 states and Puerto Rico. With approximately 23,000 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
| Last Trade: | US$16.02 |
| Daily Change: | -0.06 -0.37 |
| Daily Volume: | 1,974,453 |
| Market Cap: | US$1.450B |
November 05, 2025 August 05, 2025 May 12, 2025 February 27, 2025 October 30, 2024 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load